ArticleBlood advances2022

Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis.

Franco Locatelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.